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Activated Macrophages Promote Hepatitis C Virus
Entry in a Tumor Necrosis Factor-Dependent Manner
Nicola F. Fletcher,1 Rupesh Sutaria,2 Juandy Jo,3 Amy Barnes,1 Miroslava Blahova,2 Luke W. Meredith,1
Francois-Loic Cosset,4 Stuart M. Curbishley,2 David H. Adams,2 Antonio Bertoletti,3 and Jane A. McKeating1,2
Macrophages are critical components of the innate immune response in the liver.
Chronic hepatitis C is associated with immune infiltration and the infected liver shows a
significant increase in total macrophage numbers; however, their role in the viral life
cycle is poorly understood. Activation of blood-derived and intrahepatic macrophages
with a panel of Toll-like receptor agonists induce soluble mediators that promote hepati-
tis C virus (HCV) entry into polarized hepatoma cells. We identified tumor necrosis fac-
tor a (TNF-a) as the major cytokine involved in this process. Importantly, this effect was
not limited to HCV; TNF-a increased the permissivity of hepatoma cells to infection by
Lassa, measles and vesicular stomatitis pseudoviruses. TNF-a induced a relocalization of
tight junction protein occludin and increased the lateral diffusion speed of HCV receptor
tetraspanin CD81 in polarized HepG2 cells, providing a mechanism for their increased
permissivity to support HCV entry. High concentrations of HCV particles could stimu-
late macrophages to express TNF-a, providing a direct mechanism for the virus to pro-
mote infection. Conclusion: This study shows a new role for TNF-a to increase virus
entry and highlights the potential for HCV to exploit existing innate immune responses
in the liver to promote de novo infection events. (HEPATOLOGY 2014;59:1320-1330)
H
epatitis C virus (HCV) is a member of the
flaviviridae family and an important human
pathogen that infects hepatocytes leading to
progressive liver disease including fibrosis, cirrhosis,
and hepatocellular carcinoma. A number of antivirals
targeting the HCV replicase are in development; how-
ever, recent trials show reduced efficacy in patients
with cirrhosis or comorbidities, genotype-dependent
differences in drug sensitivity, and the emergence of
drug-resistant viruses.1,2 HCV entry into host cells
provides a conserved target for therapeutic intervention
and the potential for combination therapy with anti-
replicase drugs.1 HCV entry into the host is mediated
by molecules or receptors at the cell surface and cur-
rent evidence supports a multistep process involving
scavenger receptor class B member I, tetraspanin
CD81, and tight junction proteins claudin-1 and
occludin in HCV internalization (reviewed3,4). Recent
studies have shown the limited ability of polarized
hepatocytes to support HCV entry,5,6 highlighting a
need to understand the physiological processes that
regulate hepatocellular permeability in the infected
liver.
Inflammation is associated with chronic HCV infec-
tion and drives liver injury.7 However, with the possi-
ble exception of interferons, the role of
proinflammatory mediators in the HCV lifecycle is
poorly understood. Macrophages play an essential and
early role in sensing pathogens by way of expression of
Toll-like receptors (TLRs) that recognize pathogen-
associated molecular patterns that prime cytokine
expression, mainly interleukin (IL)21b, IL-6, and
tumor necrosis factor alpha (TNF-a).8 Kupffer cells
(KCs) are the resident macrophage of the liver and in
addition to early innate sensing of pathogens help to
maintain the tolerogenic environment of the liver.9
The chronic HCV-infected liver shows a significant
increase in total macrophage numbers that most likely
represents a local proliferation of KCs and infiltration
of bone-marrow-derived monocytes10; however, their
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role in the HCV lifecycle is poorly understood. We
demonstrate that activation of blood-derived and intra-
hepatic macrophages with a panel of TLR agonists
induce soluble mediators that promote HCV entry
into polarized hepatoma cells. We identify TNF-a as
the major cytokine involved in this process. The ability
of TNF-a to promote the permissivity of polarized
hepatoma cells was not limited to HCV but was seen
with lentiviral pseudotypes expressing Lassa, measles,
and VSV-G glycoproteins. These studies identify a
new pathway for HCV to exploit inflammatory
responses in the chronically infected liver to promote
infection that may contribute to viral persistence and
provide new targets for therapeutic intervention.
Materials and Methods
Cells and Reagents. HepG2 (American Tissue Cul-
ture Collection, Rockville, MD [ATCC]) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum. HepG2.CD81 were gen-
erated by lentiviral transduction as described, supple-
mented with 400 lg/mL Zeocin5 and polarized by
seeding at 1 3 105cells/cm2 and culturing for 5 days.5
KCs were isolated from surplus liver samples from the
liver transplant program at the Queen Elizabeth Hospi-
tal, Birmingham, UK. Peripheral CD141 monocytes
were isolated from healthy donors and stimulated as
described in the Supporting Information.13 Human
liver-associated mononuclear cells were collected from
liver washouts, surface-stained for monocyte and lineage-
positive markers, stained for TNF-a / interferon-gamma
(IFN-c) and cells characterized on a BD LSRII flow
cytometer and analyzed with FACS Diva software.
Pseudoparticle Genesis and Infection. Pseudopar-
ticles were generated by transfecting 293T cells with
plasmids encoding a human immunodeficiency virus
(HIV) provirus expressing luciferase and viral envelope
glycoproteins generated from HCV (strain H77),
Lassa, measles, and VSV-G14 or no-envelope control.15
Supernatants were harvested 48 hours posttransfection
and stored at 280C prior to infection of target cells.
HCVcc Genesis and Infection. HCV SA13/JFH
was generated and infection quantified by enumerating
NS5A-positive foci and real-time polymerase chain
reaction (PCR) detection of viral RNA as described in
the Supporting Information. HCV SA13/JFH or
mock-electroporated Huh-7.5 supernatants were col-
lected, concentrated through a Vivaspin 100,000
MWCO concentrator, overlaid on 20% sucrose, and
centrifuged for 24 hours at 23,000 rpm to purify virus
particles. Virus-containing and mock-infected superna-
tants were concentrated equally.
Viral Infection Studies. HepG2.CD81 cells were
seeded at 1 3 105 cells/cm2 and allowed to polarize
for 5 days.5 Cells were treated with conditioned
medium (CM) from peripheral macrophages, dendritic
cells (DCs), or liver-derived KCs or recombinant
human cytokines, and pseudoparticles or HCVcc
added immediately or after one 1 hour and the
cultures incubated for 72 hours. To neutralize TNF
activity, CM or recombinant cytokines were incubated
for 1 hour with anti-TNF (Infliximab; Merck; 10 lg/
mL) prior to adding to HepG2.CD81 cells. After 72
hours cells were lysed (Promega, Madison, WI) and
luciferase activity measured. Relative infectivity was
calculated by subtracting the no-envelope signal and
expressing the viral signal relative to the untreated con-
trol. To quantify HCVcc infection, viral RNA was
measured using real-time PCR and HCV antigen
expressing cells enumerated by indirect immunofluo-
rescent detection of NS5A.
Quantification of HepG2 Permeability. To deter-
mine the functionality of bile-canalicular (BC) tight
junctions, HepG2 cells were incubated with 5 lM 5-
chloromethylfluorescein diacetate (CMFDA; Invitro-
gen) at 37C for 10 minutes to allow translocation to
BC lumen. After extensive washing, the capacity of
BC to retain CMFDA was enumerated using a fluores-
cence microscope.
Confocal Imaging of Occludin Localization.
HepG2.CD81 cells were grown on 13 mm glass cover-
slips (Fisher Scientific) for 5 days and fixed with ice-
cold methanol and occludin visualized by staining
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with 2 lg/mL mouse anti-occludin (Invitrogen) and
antirabbit Alexa-Fluor 488 (Invitrogen). Nuclei were
counterstained with 40,6-diamidino-2-phenylindole
(DAPI) and mounted with ProLong Gold (Invitrogen).
Cells were viewed by laser-scanning confocal micros-
copy on a Zeiss META head microscope with a 1003
oil-immersion objective.
Fluorescent Recovery After Photobleaching (FRA-
P). HepG2 cells were transduced with AcGFP-tagged
CD8116 and allowed to polarize for 5 days on glass-
bottomed plates. Cells were treated for 1 hour with
TNF-a (100 ng/mL) and FRAP performed on a Zeiss
LSM78 confocal microscope as previously described.16
Data were imported into GraphPad Prism and fitted
using a single exponential decay algorithm, Y5Span(1-
exp(-K*X))1plateau. The diffusion coefficient (D) was
calculated using a 2D diffusion model for a circular
bleached region of interest, where D5 0.224 3
(radius2/t1/2).
Statistical Analysis. Statistical analyses were per-
formed using Student t test in Prism 6.0 (GraphPad,
San Diego, CA) with P< 0.05 being considered statis-
tically significant.
Results
Activated Macrophages Promote HCV Entry. To
assess the role of macrophages in the HCV lifecycle,
peripheral blood-derived CD141 monocytes were cul-
tured on plastic and stimulated with a combination of
IFN-c and TNF-a to generate M1-macrophages, IL-4
to generate M2-macrophages, or activated with lipo-
polysaccharide (LPS) for 24 hours. DCs were isolated
from the same donor and stimulated with LPS to
stimulate the liver microenvironment. CM was col-
lected and assessed for its effect on HCV pseudopar-
ticle (HCVpp) infection of polarized HepG2.CD81
cells. CM from LPS-stimulated macrophages, but not
DCs, significantly increased HCVpp infection, whereas
LPS alone had no effect (Fig. 1A). In contrast, IL-4 or
TNF-a/IFN-c stimulated macrophage CM had no
effect on HCVpp infectivity (Fig. 1A). Macrophages
stimulated with a range of LPS concentrations (0.1-10
lg/mL) increased HCVpp infection (Fig. 1B) and this
was consistent between donors (data not shown).
These experiments show that LPS-stimulated mono-
cyte-derived macrophages secrete soluble factors that
promote HCVpp entry.
IL-1b and TNF-a Enhance HCV Infection. To
identify the proviral factors expressed by macrophages
following LPS stimulation we quantified the expression
of 84 cytokines by PCR gene array from untreated,
IL-4, or LPS-stimulated macrophages and DCs. We
observed a different profile of cytokine messenger RNA
(mRNA) expression in macrophages stimulated with IL-
4 or LPS (Supporting Fig. 1). LPS stimulated macro-
phages to express high levels of TNF-a and low levels
of IL-1b, whereas DCs expressed several interferons
(IFN-a, IFN-b, and IFN-c) along with TNF-a (Sup-
porting Figs. 1, 2). To investigate which proinflamma-
tory cytokines promote HCVpp infection we screened a
panel of cytokines that were shown to be upregulated
in the array including IL-1b, IL-6, IL-8, IL-10, IL-17,
IL-18, TNF-a, and IFN-c (Supporting Fig. 1). Both
IL-1b and TNF-a increased HCVpp (strain H77)
infection of polarized HepG2.CD81 cells, whereas IFN-
c reduced infection in a dose-dependent manner (Fig.
Fig. 1. Conditioned media from LPS-stimulated macrophages pro-
motes HCV entry. (A) Primary macrophages (Macro) and dendritic cells
(DC) isolated from CD141 peripheral monocytes from the same donor
were stimulated with IL-4 (10 ng/mL), LPS (1 lg/mL), TNF-a/IFN-c
(10 ng/mL), or unstimulated (US) for 24 hours and conditioned media
(CM) harvested. Polarized HepG2.CD81 cells were treated with CM at
a final 1:2 dilution and infected with HCVpp. (B) Polarized HepG2-
CD81 cells were incubated with LPS alone or CM from LPS-stimulated
macrophages (Macro CM) and infected with HCVpp. Data are pre-
sented as mean infectivity6 SD relative to the untreated control (UT)
(n5 5 independent experiments). ****P< 0.0001, **P< 0.01.
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2A). TNF-a promoted infection of HCVpp expressing
a diverse panel of patient-derived envelope glycoproteins
(data not shown). Furthermore, combining IL-1b or
TNF-a with IFN-c (100 ng/mL) reduced infection to
control levels, similar to that of IFN-c alone (data not
shown). Replication of the lentiviral genome following
lipid-based delivery directly into HepG2.CD81 was not
modulated by cytokine treatment (data not shown),
demonstrating a specific effect of the cytokines on
HCV glycoprotein-dependent particle entry.
We confirmed that anti-TNF-a and anti-IL-1b neu-
tralizing antibodies inhibited the effect of recombinant
TNF-a and IL-1b on HCVpp infection (Fig. 2B).
Importantly, preincubation of LPS-stimulated macro-
phage CM with anti-TNF-a reduced HCVpp infec-
tion to a comparable level observed with untreated
hepatoma cells. The additional observation that LPS
stimulates macrophages to secrete high levels of TNF-
a (Supporting Fig. 2) supports a key role for this cyto-
kine in promoting HCV infection (Fig. 2B). In con-
trast, LPS-stimulated DCs secrete both TNF-a and
IFN-c (Supporting Fig. 2), which may explain the
modest effect of their CM on HCVpp entry (Fig. 1),
suggesting a balance between the antiviral activity of
Fig. 2. TNF-a is the major factor
secreted from activated macrophages
that promotes HCV infection. (A) Polar-
ized HepG2.CD81 cells were treated
with IL-1b, TNF-a, or IFN-c and
infected with HCVpp. (B) Neutralization
of IL-1b, TNF-a, and LPS-stimulated
macrophage CM (Macro CM) proviral
effect with anti-IL-1b (10 lg/mL) or
anti-TNF-a (10 lg/mL). (C)
HepG2.CD81 cells were pretreated with
TNF-a (10 ng/mL) and IFN-c (100 ng/
mL) for 1 or 24 hours prior to inoculat-
ing with virus or at the same time (0
hours). Data are presented as
mean6 SD relative to the untreated
control (UT) (n5 3 independent experi-
ments). ***P< 0.001, **P< 0.01.
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IFN-c and proviral effect of TNF-a. Pretreating polar-
ized hepatoma cells with TNF-a for 1 hour prior to
inoculating with virus led to a significant increase in
infection; however, a longer preincubation time of 24
hours ablated the cytokine mediated effect on HCVpp
infection, suggesting a limited response time for the
cells and/or a reversible phenotype (Fig. 2C). These
studies uncover a new role for activated macrophage
expressed TNF-a to promote HCV entry into polar-
ized hepatoma cells.
To ascertain whether TNF-a promotes infection of
authentic HCV particles, polarized HepG2.CD81 were
treated with recombinant cytokines or CM from LPS-
stimulated macrophages for 1 hour and infected with
HCV strain SA13/JFH-1 or JFH-1. Infection was quan-
tified by measuring the frequency of NS5A antigen-
expressing cells by indirect immunofluorescence and
qRT-PCR of HCV RNA. TNF-a stimulated a signifi-
cant increase in the number of HCV-infected
HepG2.CD81 cells; however, this effect was less pro-
nounced compared to the increase in viral RNA (Fig.
3A,B). To assess whether TNF-a stimulated viral repli-
cation, HepG2 cells stably replicating a blasticidin-
tagged HCV-JFH1 full-length17 were treated with
TNF-a or CM from LPS-stimulated macrophages for 3
or 24 hours. There was no significant increase in HCV
RNA levels following treatment with TNF-a or CM. In
contrast, IFN-c reduced the level of viral RNA (Fig.
3C). These experiments illustrate the role of TNF-a in
promoting the entry of authentic HCV particles with
negligible effect on genomic RNA replication.
Diverse TLR Agonists Stimulate Macrophages to
Promote HCV Infection. To date, 10 functional
TLRs have been identified in humans (TLR1-10) that
detect specific pathogen-associated molecular patterns.
To investigate whether diverse TLR agonists stimulate
macrophages to express TNF-a and promote HCVpp
infection, blood-derived macrophages were stimulated
with agonists for 24 hours and CM assessed for its
effect on HCVpp infection. Treating hepatoma cells
with agonists had no effect on HCVpp infection (data
not shown). All TLR agonists, with the exception of
CpG (TLR9), stimulated macrophages to express vary-
ing levels of TNF-a (Fig. 4A) that correlated with their
ability to promote HCVpp infection (R25 0.7313)
(Fig. 4A). Furthermore, the enhancing effect of the vari-
ous CM could be neutralized with anti-TNF (Fig. 4B).
LPS, flagellin, and ssRNA-40 stimulated macrophages
to secrete low levels of IL-1b; however the levels were
insufficient to promote HCVpp infection (Supporting
Fig. 2). Taken together, these data demonstrate that
TNF-a is the major cytokine produced by macrophages
stimulated with a variety of bacterial and viral TLRs
that promotes HCV infection.
TNF-a Promotes Entry of Diverse Viruses Into
Polarized Hepatocytes. To determine whether the
proviral effect of TNF-a is specific for HCV, we gener-
ated pseudoparticles bearing the surface glycoproteins
of Lassa, measles, and vesicular stomatitis virus (VSV).
HepG2 polarization restricted the infection of all pseu-
doparticles tested (Fig. 5A). To determine whether
TNF-a increased the number of infected cells or the
viral burden per cell, we generated VSV-G pseudopar-
ticles expressing a fluorescent reporter protein. Flow
Fig. 3. Cytokines increase HCVcc infection. HepG2.CD81 were
treated with cytokines or CM from unstimulated (US) or LPS-stimulated
macrophages and infected with HCV (SA13/JFH) for 12 hours. After
72 hours NS5A1 cells (A) and RNA levels (B) were quantified. (C) To
assess the effect of cytokines on viral replication, HepG2 cells stably
supporting HCV-JFH-1 (HepG2-JB) were treated with cytokines or CM
and HCV RNA quantified. Data are presented as mean6 SD relative
to the untreated control (UT) (n5 3 independent experiments).
***P< 0.001, **P< 0.01, *P< 0.05.
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cytometry revealed that TNF-a increased both the
number of infected cells (57%6 4.2% versus
65%6 1.8%) and their fluorescent intensity (Fig. 5B).
CM from LPS-stimulated macrophages increased the
permissivity of HepG2.CD81 cells to all pseudopar-
ticles in a TNF-dependent manner (Fig. 5C). These
results highlight the role of TNF-a in enhancing the
permissivity of polarized HepG2 cells to support infec-
tion by diverse pseudoparticles.
TNF-a Increases Hepatoma Permeability. Proin-
flammatory cytokines are known to disrupt epithelial per-
meability; however, this is largely based on gut intestinal
cell models and there is limited information for hepato-
cytes.18 We demonstrate that TNF-a and CM from LPS-
stimulated macrophages disrupted tight junction integrity,
where the latter was neutralized by anti-TNF antibody
(Fig. 6A), suggesting that TNF-a promotes HCVpp
infection by increasing HepG2 permeability. Indeed,
TNF-a and IL-1b increased the permissivity of polarized,
but not nonpolarized, HepG2.CD81 cells, supporting
this conclusion (Fig. 6B). In addition, there was minimal
effect of TNF-a or IL-1b on the permissivity of Huh-7
or Huh-7.5 hepatoma cells to support HCVpp entry,
which do not polarize in vitro.5
HepG2 cells express the tight junction protein
occludin at BC structures, representing complex
hepatocellular polarity. Treatment with TNF-a, IL-
1b, or CM from LPS-stimulated macrophages
induced a redistribution of occludin to the basolateral
membrane of HepG2.CD81 cells (Fig. 6C). In con-
trast, the cytoplasmic junctional protein ZO-1 was
unaffected (data not shown), supporting cytokine dis-
ruption of tight junctions. We previously reported
that polarization reduced viral receptor CD81 and
Fig. 4. TLR-stimulated macrophages
express TNF-a that promotes HCV entry.
(A) Peripheral macrophages were stimu-
lated with TLR agonists: Pam3CSK4
(TLR1/2)1 lg/mL; HKLM (TLR2) 108
cells/mL; PolyI:C (TLR3) 10 lg/mL;
LPS (TLR4)10 lg/mL; flagellin (TLR5)
10 lg/mL; FSL-1 (TLR6/2)1 lg/mL;
imiquimod (TLR7)10 lg/mL; ssRNA40
(TLR8) 10 lg/mL; ODN2006 (TLR9) 5
lM for 24 hours and CM assayed for
TNF-a (upper graph) and effect on
HCVpp infection of polarized
HepG2.CD81 cells (lower graph). (C)
TLR-stimulated macrophage CM was
preincubated with anti-TNF-a (10 lg/
mL) for 1 hour and evaluated for its
effect on HCVpp infection of polarized
HepG2.CD81. Data are presented as
mean6 SD relative to unstimulated
(US) control (n5 3 independent experi-
ments). ***P< 0.001, **P< 0.01,
*P< 0.05.
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HCVpp diffusion at the basal HepG2 membrane,
which may explain their reduced permissivity.16 To
investigate the effect of TNF-a on CD81 dynamics,
HepG2 were transduced to express AcGFP-CD81
and lateral diffusion at the basal membrane measured
by FRAP. TNF-a increased CD81 diffusion coeffi-
cient (Fig. 6D). Together, these data highlight a role
for TNF-a in regulating hepatoma tight junction and
CD81 dynamics, providing a mechanism for the
increase in viral permissivity.
HCV and LPS Stimulate Kupffer Cells to Express
TNF-a. Liver resident macrophages or KCs are
reported to be tolerant to LPS. We therefore compared
the sensitivity of KCs and peripheral blood-derived
Fig. 5. Cytokines increase the permis-
sivity of polarized hepatocytes to diverse
viral pseudoparticles. (A) Lassa, mea-
sles, and vesicular stomatitis virus pseu-
doparticle infection of polarized and
nonpolarized HepG2.CD81 cells. (B)
Polarized HepG2.CD81 were infected
with GFP-tagged VSV-Gpp6 TNF-a (100
ng/mL) and infected cells quantified by
flow cytometry. Mean6 SD percent of
GFP1 infected cells are shown. (C)
Lassa, measles, and VSV-G pseudopar-
ticle infection of HepG2.CD81 cells
treated with TNF-a (10 ng/mL) or CM
from unstimulated (US) or LPS-
stimulated macrophages with or without
anti-TNF-a (10 lg/mL). Data are pre-
sented as mean6 SD relative to
untreated control (UT) (n5 3 independ-
ent experiments). ***P< 0.001,
**P< 0.01, *P< 0.05.
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macrophages to LPS stimulation. KCs and peripheral-
derived cells responded to LPS and expressed compara-
ble levels of TNF-a and increased HCVpp infection
(Fig. 7). To investigate the effect of LPS on a mixed
liver immune cell population, we studied the respon-
siveness of cells harvested by perfusing normal healthy
liver donor livers prior to organ transplantation. KCs
express TNF-a but no IFN-c following LPS stimula-
tion, whereas natural killer (NK), T, or B cells from the
same donor failed to express detectable levels of TNF-a
(Fig. 7B). HCV was recently reported to activate the
inflammasome and to promote macrophage secretion of
IL-1b.19 To ascertain whether HCV could stimulate
macrophages to express TNF-a we incubated the
sinusoidal immune cell population and blood-derived
macrophages with purified virus for 24 hours. Intracel-
lular cytokine staining showed that HCV induced sinu-
soidal KCs to express TNF-a, whereas mock treatment
had no effect (Fig. 7D). High concentrations of HCVcc
particles stimulate macrophages to secrete TNF-a that
had no detectable effect on HCVpp entry (Fig. 7B),
implying that the levels of biologically active TNF-a are
too low to be effective or that the virus stimulates mac-
rophages to express additional antiviral mediators.
Taken together, these data highlight a role for HCV
particles and bacterial products in the liver environment
to induce a proinflammatory environment that pro-
motes HCV infection.
Fig. 6. Effect of TNF-a on HepG2 permeability, occludin localization, and CD81 lateral diffusion. (A) Polarized HepG2.CD81 were treated with
cytokines or CM from unstimulated (US) or LPS-stimulated macrophages, with or without anti-TNF-a (100 lg/mL) and tight junction integrity
quantified. (B) Effect of IL-1b or TNF-a on HCVpp infection of polarized or nonpolarized HepG2.CD81. Data are expressed relative to untreated
(100%) polarized or nonpolarized control. (C) Occludin localization in HepG2.CD81 cells following cytokine or CM treatment, where scale
bar5 10 lm. (D) AcGFP-CD81 diffusion speed in untreated (UT) or TNF-a treated polarized HepG2 cells, where each symbol represents an inde-
pendent bleach spot. The median values are shown. **P< 0.01, *P< 0.05.
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Discussion
We describe a new mechanism for HCV to use
TNF-a to promote infection of polarized hepatocytes.
Several TLR agonists including LPS stimulate
macrophages to secrete cytokines including IL-1b and
TNF-a that promote HCV infection. In contrast, LPS
activates DCs to secrete high levels of IFN-c,20 a cyto-
kine with antiviral activity, explaining the negligible
effect of DC conditioned media on HCV entry. Given
Fig. 7. Kupffer cells express TNF-a but not IFN-c following LPS and HCV stimulation. (A) Intrahepatic KCs or peripheral blood-derived macro-
phages were stimulated for 24 hours with LPS (10 lg/mL), CM collected and assayed for TNF-a (upper graph), and effect on HCVpp infection of
polarized HepG2.CD81 cells (lower graph). (B) Intrasinusoidal monocytes and lineage-positive (T-NK-B) cells were stimulated with LPS (10 lg/
mL) for 6 hours and intracellular TNF-a and IFN-c expression assessed by flow cytometry. (C) Intrahepatic KCs or peripheral blood-derived macro-
phages were incubated with HCV (strain SA13/JFH) or mock at an estimated multiplicity of 22 (Neat) or 2.2 (1:10), as defined by HCV-RNA cop-
ies/cell. CM was collected and assayed for TNF-a (upper graph) and effect on HCVpp infection of polarized HepG2.CD81 cells (lower graph). (D)
Intrasinusoidal monocytes and lineage-positive (T-NK-B) cells were stimulated with HCV (neat) or mock antigen for 6 hours and intracellular TNF-
a and IFN-c expression assessed by flow cytometry. Data are represented as mean6 SD (n5 2 independent experiments). ***P< 0.001,
**P< 0.01, *P< 0.05.
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the constant stimulation of hepatic TLR4 with gut-
derived LPS the liver is thought to have developed tol-
erance mechanisms to limit hyperactivation of the
immune system.21 However, recent studies demon-
strate a loss of TLR tolerance in macrophages from
chronic hepatitis B and C-infected patients, reporting
an association between LPS-induced macrophage acti-
vation and progression to endstage liver disease.22,23 It
is interesting to note that alcohol24 and HIV coinfec-
tion25 are both associated with increased levels of
plasma LPS. Our demonstration that LPS stimulates
KCs to promote HCV infection provides a potential
explanation for how these comorbidities may augment
HCV infection and ensuing liver disease.
The major cell type within the liver supporting
HCV replication is the polarized hepatocyte. HCV
enters hepatocytes by way of a multistep process that
involves two tight junction proteins, claudin-1 and
occludin, that reside within BC structures that are
poorly accessible to virus entering the liver by way of
the sinusoidal blood. This model of virus internaliza-
tion by way of the hepatocellular tight junction26 is
consistent with our earlier observation that hepatoma
polarization restricts HCV entry. Our recent report
that hepatoma polarization reduces CD81 and
HCVpp dynamics at the basal membrane compared to
nonpolarized cells16 highlights a role for membrane
protein dynamics in limiting HCV infection of polar-
ized epithelia. Inflammatory cytokines including TNF-
a permeabilize epithelia and increase the exposure of
underlying tissues to luminal antigens in sites such as
the gut and airway, resulting in a multitude of disease
states including inflammatory bowel disease, asthma,
and cystic fibrosis.27,28 TNF-a disrupted HepG2 tight
junction integrity with a concomitant relocalization of
occludin and increase in CD81 dynamics.16,29 These
data are consistent with reports of TNF-a inducing
tight junction disassembly in epithelia by way of NF-
jB-dependent activation of myosin light chain kinase
(MLCK) transcription and MLC phosphorylation.30,31
We did not observe any effect of TNF-a on HCV rep-
lication, suggesting that increased virus entry does not
lead to quicker sensing of HCV and reduction of viral
replication. Our observation that TNF-a promotes the
entry of several pseudoviruses to polarized hepatoma
cells suggests that TNF-a affects the function or distri-
bution of several different classes of viral receptors,
most likely through modulating membrane receptor
trafficking.
Adenovirus was recently shown to activate macro-
phages to express IL-8, leading to a relocalization of
basolateral and junctional expressed viral receptors,
avb3-5 integrins and CAR, respectively, to the apical
surface increasing virus binding and internalization.32
We demonstrate that HCV can activate macrophages
to express TNF-a; however, the level of secreted TNF-
a was insufficient to prime infection and was signifi-
cantly lower than observed with other TLR agonists.
Negash et al.19 recently reported that HCV can acti-
vate the inflammasome and promote macrophages to
secrete IL-1b. We confirm these observations; however,
the levels of IL-1b were low and had minimal effect
on HCVpp infection. Several publications report that
HCV induces TNF-a and IL-1b expression in hepato-
cytes,33,34 providing an additional pathway for HCV
to promote cytokine expression. These data highlight
the potential for HCV to exploit preexisting inflamma-
tory responses to prime viral infection and transmis-
sion within the liver.
We used a therapeutic anti-TNF-a monoclonal anti-
body (infliximab) to neutralize the effect of LPS-
stimulated macrophages on viral infection. This and
similar antibodies have been used to treat HCV-infected
patients with chronic inflammatory conditions such as
rheumatoid arthritis and Crohn’s disease.35 One phase
II trial reported that the anti-TNF-a antibody etaner-
cept in combination with interferon and ribavirin signif-
icantly reduced HCV replication, with undetectable
levels of HCV RNA in 63% of etanercept-treated
patients after 24 weeks, compared with 32% of patients
receiving interferon and ribavirin therapy.36 Despite the
well-recognized role of TNF-a in liver injury it has an
equally important function in immune protection, high-
lighted by the enhanced susceptibility of patients with
alcoholic liver disease to infectious agents. TLR antago-
nists have been used to treat a number of diseases37 and
our study highlights a potential role for TLR4 antago-
nists to treat viral hepatitis.38
In conclusion, we demonstrate a new pathway for
HCV to exploit macrophage-expressed TNF-a to
promote infection. TNF-a plays a key role in regulat-
ing cell differentiation, proliferation, innate and
adaptive immune responses, and is expressed by a
variety of immune cells. TNF gene polymorphism
has been reported to influence serum levels of TNF
and to affect susceptibility to various diseases.39 Our
studies uncover a new role for TNF-a and IL-1b in
promoting HCV infection of polarized hepatocytes
and provide new therapeutic targets for antiviral
therapy.
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